KALA BIO, Inc. (KALA)
NASDAQ: KALA · Real-Time Price · USD
0.1988
-0.0270 (-11.96%)
At close: Apr 15, 2026, 4:00 PM EDT
0.1963
-0.0025 (-1.26%)
Pre-market: Apr 16, 2026, 5:19 AM EDT
KALA BIO Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
38
Market Cap
5.62M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 3.89M | -7.35M | -65.37% |
| Dec 31, 2021 | 11.24M | 4.88M | 76.67% |
| Dec 31, 2020 | 6.36M | 288.00K | 4.74% |
| Dec 31, 2019 | 6.07M | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | 45.00K | -410.00K | -90.11% |
| Dec 31, 2014 | 455.00K | 405.00K | 810.00% |
| Dec 31, 2013 | 50.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jaguar Health | 11.51M |
| Moolec Science | 7.83M |
| 60 Degrees Pharmaceuticals | 1.41M |
| XTL Biopharmaceuticals | 968.00K |
| Bio Green Med Solution | 747.00K |
| Cardio Diagnostics Holdings | 14.83K |
| Ernexa Therapeutics | 1,000.00 |
KALA News
- 14 days ago - Kala Bio Engages Dr. Saeid Babaei as Senior Scientific Advisor to Evaluate Clinical Assets and Precision Development Opportunities - GlobeNewsWire
- 16 days ago - KALA BIO Delivers Industry-Leading AI Infrastructure: Bionic Intelligence Research Agent Now Live - GlobeNewsWire
- 16 days ago - EXCLUSIVE: Penny Stock Kala Bio Transitions To Revenue Model With AI Platform Launch - Benzinga
- 4 weeks ago - Red Light Holland Engages Kala Bio's Researgency.AI Platform to Support Clinical Development of Filament's Patented PEX010 Botanical Psilocybin Drug Candidate - GlobeNewsWire
- 4 weeks ago - Red Light Holland Engages Kala Bio's Researgency.ai Platform to Support Clinical Development of Filament Health's Patented PEX010 Botanical Psilocybin Drug Candidate - Newsfile Corp
- 5 weeks ago - Younet.ai Highlights Researgency.ai Collaboration with Kala Bio (KALA) as New "AutoResearch" Milestone Signals the Rise of Autonomous Research Agents - Newsfile Corp
- 5 weeks ago - Kala Bio Launches a Revolution for Biotech- First AI Agent Deploying in 14 Days as $180 Billion Agentic AI Healthcare Revolution Accelerates - GlobeNewsWire
- 6 weeks ago - KALA BIO Announces Strategic Initiative to Deploy and Continue to Develop an On-Premises AI Infrastructure Platform for the Biotech Industry; Enters Into Platform Development and Exclusive License Agreement for Proprietary AI Research Platform “Researgency” - GlobeNewsWire